TCRX
Tscan Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$75.73M
P/E Ratio
—
EPS
$-1.00
Beta
1.01
52W High
$2.57
52W Low
$0.88
50-Day MA
$1.09
200-Day MA
$1.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tscan Therapeutics Inc
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company committed to revolutionizing cancer treatment through its advanced T cell receptor (TCR) discovery platform, which targets specific cancer antigens for precision immunotherapy solutions. The firm’s innovative approach aims to translate cutting-edge scientific research into effective TCR-based therapeutics, enhancing treatment options for a variety of malignancies. With a robust pipeline and a solid intellectual property portfolio, Tscan Therapeutics is strategically positioned to become a key player in the fast-growing sector of T cell-based cancer therapies, addressing significant unmet medical needs and improving patient outcomes.
Fundamentals
| Revenue (TTM) | $10.32M |
| Gross Profit (TTM) | $-102.22M |
| EBITDA | $-130.95M |
| Operating Margin | -852.00% |
| Return on Equity | -71.30% |
| Return on Assets | -27.90% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $2.16 |
| Price-to-Book | 0.61 |
| Price-to-Sales (TTM) | 7.33 |
| EV/Revenue | 1.691 |
| EV/EBITDA | 0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 286.00% |
| Shares Outstanding | $55.83M |
| Float | $47.79M |
| % Insiders | 0.21% |
| % Institutions | 61.98% |
Historical Volatility
HV 10-Day
142.46%
HV 20-Day
101.17%
HV 30-Day
87.77%
HV 60-Day
79.60%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($6.00 target)
1
Strong Buy4
Buy1
HoldData last updated: 4/29/2026